GRATRYL 3 mg/3ml Solution for I.V. Injection or Infusion

Used for the treatment of hypocalcemia and secondary hyperparathyroidism in patients undergoing chronic renal dialysis. It improves renal osteodystrophy by reducing parathyroid hormone levels.

Treatment of primary carnitine deficiency and secondary carnitine deficiency in patients undergoing hemodialysis.

It is indicated in adults for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. It is also used in pediatric patients aged one month and older for the prevention of acute nausea and vomiting associated with highly emetogenic chemotherapy and for the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy.

Used for the treatment of hypocalcemia and secondary hyperparathyroidism in patients undergoing chronic renal dialysis. It improves renal osteodystrophy by reducing parathyroid hormone levels.